

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Preparation of Oligonucleotides Containing 5-Bromouracil and 5-Methylcytidine.

E. Ferrer^{ab}; C. Fàbrega^{ab}; R. G. Garcia^b; F. Azorín^a; R. Eritja^{ab}

^a Centro de Investigación y Desarrollo, Barcelona, Spain ^b European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

To cite this Article Ferrer, E. , Fàbrega, C. , Garcia, R. G. , Azorín, F. and Eritja, R.(1996) 'Preparation of Oligonucleotides Containing 5-Bromouracil and 5-Methylcytidine.', *Nucleosides, Nucleotides and Nucleic Acids*, 15: 4, 907 — 921

To link to this Article: DOI: 10.1080/07328319608002137

URL: <http://dx.doi.org/10.1080/07328319608002137>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**PREPARATION OF OLIGONUCLEOTIDES CONTAINING
5-BROMOURACIL AND 5-METHYLCYTIDINE.**

Elisenda Ferrer^{1,2}, Carme Fàbrega^{1,2}, Ramon Güimil Garcia², Ferran Azorín¹ and
Ramon Eritja^{*,1,2}.

¹Centro de Investigación y Desarrollo, CSIC. Jordi Girona 18. 08034 Barcelona. Spain.

²European Molecular Biology Laboratory (EMBL). Meyerhofstrasse 1, D-69117
Heidelberg. Germany.

Abstract: A previously described side reaction on 5-bromouracil during standard oligonucleotide deprotection conditions has been studied in detail. The side product, 5-amino-2'-deoxyuridine, is isolated and characterized. The use of several 5-methylcytidine protected derivatives for the preparation of oligonucleotides containing 5-bromouracil and 5-methylcytidine free of 5-amino-2'-deoxyuridine is discussed.

Several years ago, it was shown that oligonucleotides could bind to specific sequences on double stranded DNA by forming triple helices. Although triple helix formation is restricted to homopurine-homopyrimidine sequences a large effort is being done in order to use oligonucleotides to bind specific genomic sequences. The potential applications of the triple helix formation has been recently reviewed^{1,2}.

Substitution of some natural bases for base analogues may improve the binding and/or change the specificity. For example it has been demonstrated that substituting 5-methylcytosine (m⁵C) to cytosine increases the affinity of homopyrimidine oligodeoxynucleotides for its recognition sequence in duplex DNA and extends the pH range in where triple helix is stable to neutral pH^{3,4}. A similar effect has been described for the substitution of 5-bromouracil (Br⁵U) to thymine⁴. Incorporation of both m⁵C and Br⁵U resulted in a large increase of triple helix formation over an extended pH range⁴.

For these reasons we were interested in preparing homopyrimidine oligonucleotides containing both m⁵C and Br⁵U. During the synthesis of an oligonucleotide containing Br⁵U for NMR studies using the phosphotriester method, a partial conversion of Br⁵U

was found while using the standard ammonia treatment (overnight at 55 °C) to an unknown derivative⁵. When ammonia deprotection was performed for 3 days at 37 °C, no side product was detected⁵. Recently, similar results were found using phosphoramidite chemistry⁶ and the decomposition of Br⁵U was avoided by using phosphoramidites protected with more labile groups such as phenoxyacetyl (Pac) and isobutyryl groups⁷ and performing the ammonia deprotection at room temperature⁶. In this communication we will describe the characterization of the side product obtained during the ammonia treatment of Br⁵U and the preparation of a new m⁵C phosphoramidite derivative designed for the preparation of oligonucleotides containing both Br⁵U and m⁵C free of side products coming from decomposition of Br⁵U.

RESULTS AND DISCUSSION

Characterization of the main decomposition product of 5-bromo-2'-deoxyuridine during ammonia treatment at 55°C.

Previous reports on the synthesis of oligonucleotides containing 5-bromouracil have described the formation of a side reaction during the ammonia deprotection at 55°C^{5,6}. The side reaction was detected by the appearance of a new nucleoside during the HPLC analysis of the enzyme digestion of the oligonucleotide⁶. The new nucleoside eluted near the dC peak and the integration of the peaks indicated the presence of a 10-20% of the modified oligonucleotide in which 5-bromouracil was converted to another product^{5,6}. When deprotection was run at lower temperature, no side product was detected. When deprotection of oligonucleotides was done by treatment with a 1:1 ethylenediamine/ethanol solution at room temperature for 6 hours, a different Br⁵dU side product was formed in approx. 50% yield (data not shown). The modified oligonucleotide was easily separated from the correct sequence by gel electrophoresis and ion-exchange chromatography indicating that a ethylenediamine molecule (and subsequently a positive charge) was added to the oligonucleotide. All these data indicated that the side product arose from the addition to 5-bromouracil of one molecule of the amine used during the deprotection. This addition could only happen at positions 5 and 6 of the pyrimidine ring of 5-bromouracil. It has been described that 5-aminouridine could be isolated from the reaction of 5-bromouridine with liquid ammonia at high pressure and temperature⁸. Also 5-aminocytosine is the main product from the reaction of 5-bromocytosine with liquid ammonia together with some small amounts of 6-aminocytosine⁹. So most likely the side




FIGURE 1: Conversion of 5-bromo-2'-deoxyuridine to 5-amino-2'-deoxyuridine in aqueous ammonia solutions .

product formed during the ammonia deprotection of the oligonucleotides containing Br⁵U is the corresponding 5-amino-2'-deoxyuridine oligonucleotide.

In order to confirm the formation of this product, 5-bromo-2'-deoxyuridine (Br⁵dU) was treated with 33% concentrated ammonia solution at 55°C for 4 days. The crude mixture was analysed by HPLC and a product with the same retention time and UV absorption properties than the side product observed in the Br⁵U oligonucleotide enzyme digestions was found. The area of the peak of the side product was found to be equal to the area of peak of the remaining Br⁵dU. The side product was isolated by semi-preparative HPLC in sufficient amounts for characterization. Mass spectrometry confirmed a molecular weight in agreement with the structure of 5- or 6-amino-2'-deoxyuridine (M^+ found 244.2, expected 244.2) and spectroscopic data (U.V. absorption spectra, ¹H and ¹³C-NMR) were in agreement with published data for 5-aminouridine⁸ and different from data described for 6-aminouridine^{9,10}. So, similarly to what has been described for the reaction of Br⁵dU with liquid ammonia⁸, 5-amino-2'-deoxyuridine was the modified nucleoside obtained in 10-20% yield during the deprotection of Br⁵dU oligonucleotides (FIGURE 1). Also when 5-iodo-2'-deoxyuridine was treated with 33% ammonia solution at 55 °C, the same side product was obtained (data not shown). On the other hand, it has been described that oligonucleotides carrying 5-fluorouracil does not produce any side product during the ammonia deprotection⁶. All this data are in agreement with the addition-displacement-elimination mechanism postulated by Goldman and Kalman to explain the formation of 5-aminocytidine from 5-bromocytidine⁹.

Table 1: Preparation of (Br⁵dU-m⁵dC)₉ using commercially available phosphoramidites.

| Phosphoramidites | Ammonia treatment | % Modification |
|---|---|---|
| Br ⁵ dU, m ⁵ dC ^{bz} | conc. NH ₃ , 55°C, 16hr | 15% Br ⁵ dU->NH ₂ ⁵ dU |
| Br ⁵ dU, m ⁵ dC ^{bz} | conc. NH ₃ /EtOH, 55°C, 16hr | 10% Br ⁵ dU->NH ₂ ⁵ dU |
| Br ⁵ dU, m ⁵ dC ^{bz} | conc. NH ₃ , R.T., 3 days | 5% Br ⁵ dU->NH ₂ ⁵ dU |
| Br ⁵ dU, T ^{tri} | conc. NH ₃ , R.T., 16hr | 12% T ^{tri} ->T |

Preparation of oligonucleotides with both 5-bromouracil and 5-methylcytidine.

It has been described that the use of phosphoramidites with more labile phenoxyacetyl (Pac) and isobutyryl (ibu) protecting groups allowed the deprotection of oligonucleotides at room temperature⁷ and, for that reason, oligonucleotides carrying Br⁵dU could be prepared without apparent decomposition of Br⁵dU⁶. Unfortunately, neither phenoxyacetyl or isobutyryl groups have been described for the protection of m⁵dC. The only commercially available m⁵dC phosphoramidite derivative was protected with the rather stable benzoyl group. In preliminary experiments, the octadecamer A (Br⁵dU-m⁵dC)₉ was prepared using the commercially available m⁵dC^{bz} phosphoramidite and the 4-(1,2,4-triazolyl)thymidine phosphoramidite (T^{tri})^{12,13} as precursors of m⁵dC. Milder deprotection conditions were assayed to obtain oligonucleotides with both 5-bromouracil and 5-methylcytidine. Results are summarised in table 1. The percentage of modification was calculated from the enzyme digestion of the HPLC-purified oligonucleotide.

As described previously^{5,6}, the use of standard ammonia deprotection conditions (conc. NH₃, 55°C, 16hr) yielded a mixture of oligonucleotides in which 15% of the Br⁵dU molecules were converted to NH₂⁵dU. Because there are nine Br⁵dU molecules in the oligonucleotide, a 15% modification implies that only a few molecules are the desired (Br⁵dU-m⁵dC)₉ oligonucleotide. On the contrary, the product obtained was a mixture of oligonucleotides that instead of Br⁵dU contained one or two NH₂⁵dU molecules. It has been suggested¹¹ that performing the ammonia treatment with a 3:1 mixture of conc. NH₃ / ethanol, could improve the quality of the product and we have found a reduction of the formation of the side product from 15% to 10%. Unfortunately, in our case a 10% side reaction implied that the octadecamer was only 10-20% pure. When ammonia treatment was performed at room temperature for 3 days, a cleaner product was obtained (only 5%

side product), but with low yield, because some new products appeared at the back of the main peak that made the separation difficult. These products could be oligonucleotides containing still some of the benzoyl groups but there was not enough material to characterize them. Finally, the use of the triazolyl derivative of thymidine^{12,13} as a source of m⁵dC was not satisfactory because 12% of T was obtained. This product could be obtained as side product by hydrolysis instead of the desired ammonolysis, but also T phosphoramidite could be present as minor contamination of the triazolyl T phosphoramidite. All this preliminary data shows the need to find a more labile protecting groups for m⁵dC for the preparation of oligonucleotides containing several molecules of Br⁵dU together with m⁵dC.

In order to obtain m⁵dC phosphoramidite derivatives, m⁵dC and DMT-m⁵dC were prepared from T and DMT-T following the method described by Sung¹⁵. The method involved protection of the alcohol functions with trimethylsilyl or acetyl groups and formation of the 4-(1,2,4-triazolyl) thymidine derivative. Treatment of this intermediate with ammonia, yield the desired m⁵dC. A similar protocol was applied to 5'-O-DMT-T to obtain 5'-O-DMT-m⁵dC. Protection of the 3'-OH was done by reaction with trimethylsilyl-1,2,4-triazole followed by the formation of the 1,2,4-triazolyl derivative. Ammonolysis with ammonia in dioxane gave 5'-O-DMT-m⁵dC in 76 % yield.

It has been described¹⁴ that T could be transformed in a one pot reaction to m⁵dC by heating T with hexamethyldisilazane, formamide and ammonium sulphate at 140 °C for 60 hours. We found this protocol not suitable, because low recoveries of the product were obtained and the product was impurified with large amounts of the depyrimidation product : 5-methylcytosine (data not shown).

Protection of position 4 of m⁵dC with isobutyryl (ibu) groups was studied. 5'-O-DMT-m⁵dC was reacted with trimethylsilyl chloride in pyridine and isobutyric anhydride obtaining after purification the desired isobutyryl derivative in a moderate yield (42%).

A small part of 5'-O-DMT-N⁴-ibu-m⁵dC was detritylated to obtain N⁴-ibu-m⁵dC. Stability of the isobutyryl m⁵dC derivative to ammonia was studied by HPLC. At 50 °C, N⁴-ibu-m⁵dC was converted to m⁵dC with a half-life of 4 hours. At room temperature the half-life was approx. 10 hours. When this result was compared with the 30 minutes half-time described for the isobutyryl derivative of dC at room temperature⁷, we concluded that in our case the isobutyryl group was too stable for the protection of m⁵dC. Also protection of position 4 with the phenoxyacetyl (pac) group was attempted. As described for the pac derivative of dC⁷, low yields were obtained indicating that decomposition was occurring during silica gel chromatography (data not shown).




FIGURE 2: 5-Methyl-2'-deoxycytidine derivatives prepared in this work.

Afterwards, the base labile fluorenylmethoxycarbonyl (Fmoc)¹⁶ and *p*-nitrophenylethoxycarbonyl (Npeoc)¹⁷ groups were tested for the protection of the amino group of m⁵dC. These groups could be removed with non-nucleophilic bases through a β -elimination mechanism. When a strong non-nucleophilic base like DBU is used for the removal of this group no side reaction should happen at Br⁵dU moiety. Fmoc and Npeoc groups were introduced at position 4 of m⁵dC using the transient protection method¹⁶ obtaining the desired Fmoc and Npeoc derivatives of m⁵dC with moderate yields (59% for Npeoc and 20% for Fmoc). The protection of the 5'-OH function with the dimethoxytrityl group was accomplished using standard protocols¹⁸. Small aliquots of DMT-protected nucleosides were treated with a 0.5 M DBU solution in dioxane in order to investigate the deprotection reaction. It was found that the Fmoc group was quantitatively removed in 5 minutes and the Npeoc group in 4 hours. For this reason, the Fmoc group was selected. The preparation of the phosphoramidite derivative of DMT-N⁴-Fmoc-dC needed for the DNA synthesis was performed following standard protocols¹⁸.

Octadecamer A [5'(Br⁵dU-m⁵dC)₉3'] and elevenmer B (5' m⁵dC-Br⁵dU-Br⁵dU-m⁵dC-m⁵dC-Br⁵dU-m⁵dC-m⁵dC-Br⁵dU-m⁵dC-Br⁵dU 3') sequences were made on an automated DNA synthesiser using the commercially available Br⁵dU phosphoramidite and N⁴-Fmoc-m⁵dC phosphoramidite prepared in this work. Average coupling yield of the m⁵dC phosphoramidite measured by DMT absorbance was 95% while Br⁵dU coupling yield was 99%. After the synthesis, the solid supports were treated with a 0.5M DBU




FIGURE 3 : Absorbance vs temperature plot for the $h_{26}.s_{11}$ - m^5CBr^5U triplex (see table 2) in 1M NaCl, 100 mM sodium phosphate / citric acid buffer at pH 6.5.

solution in dichloromethane for 15 minutes to remove the Fmoc group. After subsequent washings, the supports were treated with concentrated ammonia for 16 hours at room temperature. The resulting oligonucleotides with the DMT group at the 5'-end were purified by using COPTM cartridges. Purified oligonucleotides were analysed by HPLC and enzyme digestion showed a correct nucleoside composition and the absence of 5-amino-dU.

The influence of the presence of Br^5dU and m^5dC on triple helix formation was studied with the sequence described by Xodo *et al.*³ Triple helix were formed by mixing the hairpin molecule (h_{26}) with different single stranded 11-mers (s_{11}) which contain T, C, Br^5dU and m^5C . The ultraviolet absorbance at 270nm was then followed as a function of temperature at different pH values³. At pH 5.5-6.5, two clear transitions were observed (FIGURE 3). As described by Xodo *et al.*³, the first transition is due to the dissociation of s_{11} from h_{26} (triplex to duplex) and the second transition to the denaturation of h_{26} (duplex to single strand). The results in table 2 show that the triplex dissociation is strongly dependent on the pH, because C and m^5C need to be protonated in order to form triple helix. As previously described,^{3,4,19} m^5C stabilize the triple helix. We observed that melting temperatures of triple helix dissociation in $h_{26}.s_{11}$ - m^5CT are 20-30 degrees higher

Table 2: Melting temperatures for the triplex $h_{26} : s_{11}$ in 1M NaCl, 100 mM sodium phosphate/ citric acid buffer.



| | | Triplex T _m values (°C) ^a | | | |
|--|--------|---|--------|--------|--|
| Sequence | pH 5.5 | pH 6.0 | pH 6.5 | pH 7.0 | |
| X = C, Y = T | 53 | 20 | -- | -- | |
| X =m ⁵ C, Y = T | 58 | 38 | 30 | -- | |
| X = C, Y = Br ⁵ U | 55 | 35 | 28 | -- | |
| X =m ⁵ C, Y = Br ⁵ U | 74 | 45 | 39 | 20 | |

^aThe duplex T_m values occurred between 80°C (pH 7.0) and 75°C (pH 5.5).

than h₂₆-s₁₁-CT. Substitution of T for Br⁵U has a similar effect . Substitution of both C and T for m⁵C and Br⁵U has a strong stabilizing effect and therefore triple helix dissociation could be observed at pH 7.0. These results are similar to what has been described by Povsic and Dervan.⁴

In conclusion, we have isolated and characterized a side product observed during the preparation of oligonucleotides containing Br⁵dU. Although the side product is formed in small amounts (10-20%), it could become important if the number of Br⁵dU molecules in the oligonucleotide is high. Due to the triple helix stabilizing properties of Br⁵U and m⁵C, we have developed protected derivatives of m⁵dC that can be used for the preparation of oligonucleotides containing Br⁵dU and m⁵dC free of side products. The method described here exploits the use β -elimination groups for the protection of the amino function of m⁵dC. As described by Pfeleiderer,¹⁷ these groups can be removed by non-nucleophilic bases that makes them suitable for the preparation of oligonucleotides containing ammonia-sensitive bases. Although in this work we have used the Fmoc derivative because it is more labile, the Npeoc derivative could also be advantageous because it can be isolated in better yields and still be removed in a reasonable time. The method described here could be of interest for other oligonucleotide derivatives that contain 5-bromouracil²⁰.

EXPERIMENTAL SECTION

Abbreviations used: AcOEt: ethyl acetate, Br⁵U: 5-bromouracil, Br⁵dU: 5-bromo-2'-deoxyuridine, CPG: controlled-pore glass, DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene, DCM: dichloromethane, DMF: N,N-dimethylformamide, DMT: dimethoxytrityl, EtOH: ethanol, Fmoc: 9-fluorenylmethoxycarbonyl; ibu: isobutyryl, LCAA: long chain amino alkyl, m⁵C: 5-methyluracil, m⁵dC: 5-methyl-2'-deoxyuridine, MeOH: methanol, Npeoc: 2-(4-nitrophenyl)ethoxycarbonyl, NH₂⁵dU: 5-amino-2'-deoxyuridine, pac: phenoxyacetyl, THF: tetrahydrofuran, T^{tri}: 4-(1,2,4-triazol-1-yl)pyrimid-2-one 2'-deoxyriboside.

Isolation of 5-amino-2'-deoxyuridine by treatment of 5-bromo-2'-deoxyuridine with aqueous ammonia.

5-Bromo-2'-deoxyuridine (20 mg, 0.065 mmol) was treated with concentrated aqueous ammonia (32%, 1 ml) at 55 °C for 4 days in a screw-cap vial. The reaction mixture was cooled and concentrated to dryness. The residue was dissolved in water and purified by analytical HPLC. Column: Lichrospher 100 RP-18, 10 µm, 250 x 4 mm. Solvent A: water, solvent B: acetonitrile / water (1:1). A 20 minutes linear gradient from 5 to 50% B. A new product was observed with a lower retention time. Retention times: peak 1 (characterised as 5-amino-dU) 4.9 min, peak 2 (characterised as the starting material, 5-bromo-dU) 12 min. The area ratio between the two peaks was approximately 1:1. The newly formed product was isolated after repeated injections obtaining 34 absorbance units at 290 nm. Taking into account the extinction coefficient described by Roberts and Visser⁸ for 5-amino-dU (8.600), the amount isolated was 0.96 mg (6%). UV(water / acetonitrile) λ_{max} = 292.9 nm. ¹H-NMR (D₂O, 300 MHz): 7.24 (1H, s), 6.25 (1H, t, J = 5.8 Hz), 4.38 (1H, m), 3.94 (1H, m), 3.71 (2H, m), 2.28 (2H, m). ¹³C-NMR (D₂O, 75 MHz): 160.4, 142.2, 114.0, 112.5, 78.2, 76.7, 62.3, 53.0, 38.4. Mass spectrum (electrospray): 244.2 (M + 1), 266.3 (M + Na), 282.3 (M + K).

5-Methyl-2'-deoxycytidine (1).

Thymidine (1.41 g, 5 mmol) was suspended in 50 ml of DCM and 8.4 ml (60 mmol) of triethylamine were added followed by 6.2 ml (50 mmol) of trimethylsilyl chloride. After 30 min of magnetic stirring, the reaction mixture was poured with stirring in cold 1M aqueous NaHCO₃. Phases were separated, the organic phase was dried and evaporated to dryness. The residual brown oil was dried with evaporation of toluene three times and the residue was used without further purification.

1,2,4-Triazole (3.2 g, 46.3 mmol) was suspended in 100 ml of acetonitrile and the mixture was placed on an ice-bath. 1 ml of POCl_3 (10.7 mmol) was added followed by 10 ml of triethylamine (72 mmol). After 30 min of magnetic stirring, previously prepared bis(trimethylsilyl)thymidine was dissolved in dry acetonitrile and added to the phosphoryl tris(1,2,4-triazolide) solution. The reaction was stirred two hours at room temperature and solvents were concentrated. The residue was dissolved in DCM and the solution was washed with 1 M aqueous NaHCO_3 . The organic phase was dried and concentrated to dryness. The presence of the triazolyl derivative was observed by its fluorescence properties on TLC plates. The residue was dissolved in THF (200 ml) and the solution was treated with ammonia in a stainless steel bomb for three days at 70 °C. The cooled bomb was opened carefully and solvent was evaporated. A mixture of 40% MeOH in CHCl_3 was used to dissolve the residual product left in the bomb and the washings were combined with the product previously obtained. The product was purified by column chromatography on silica gel, eluting with a gradient from 6% to 25% MeOH in CHCl_3 . Yield: 1.1 g (4.6 mmol, 92%). TLC (20% EtOH / DCM): Rf 0.2. $^1\text{H-NMR}$ (CD_3OD , 200 MHz): 7.6 (1H, s), 6.25 (1H, dd), 5.25 (1H, m), 4.4-4.2 (3H, m), 2.6-2.2 (2H, m), 1.95 (3H, s). $^{13}\text{C-NMR}$ (DMSO-d_6 , 62.9 MHz): 165.3, 155.2, 138.3, 101.3, 87.1, 84.7, 70.4, 61.3, 40, 13.2.

5'-O-(4,4'-Dimethoxytrityl)-5-methyl-2'-deoxycytidine (2).

DMT-T (1 g, 1.83 mmol) was dissolved in 42 ml of dry acetonitrile and 0.52 g (3.8 mmol) of N-trimethylsilyl-1,2,4-triazole were added. After 1 hour of magnetic stirring at 55 °C, the solution was cooled at room temperature and added to a solution of phosphoryl tris(1,2,4-triazolide) previously prepared as follows: To an ice-cooled suspension of 1.28 g (18.5 mmol) of 1,2,4-triazole in acetonitrile (20 ml), 615 mg (0.36 ml, 3.96 mmol) of POCl_3 and 2.81 ml (20 mmol) of triethylamine were added. The mixture was kept on ice for 30 minutes with stirring. After the addition of the solution of DMT-nucleoside, the mixture was kept at room temperature for 4 hours. The progress of the reaction was monitored by TLC for the appearance of a highly fluorescent derivative with a slightly higher Rf. Afterwards, the reaction mixture was concentrated to dryness. The residue was treated with 5% NaHCO_3 solution and DCM. The organic phase was separated and dried. The product was used without further purification. Yield : 0.9 g (72%). TLC (5% MeOH in DCM) Rf 0.4. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): 8.3 (1H, s), 8.02 (1H, s), 7.6 (1H, s), 7.55-6.88 (9H, m), 6.75 (4H, d, $J=8.7$), 6.30 (1H, t, $J=6.9$), 4.42 (1H, m), 4.02 (1H, m), 3.72 (6H, s), 3.46 (2H, m), 2.6 (1H, m), 1.9 (3H, s), 0 (9H, s). $^{13}\text{C-NMR}$ (CDCl_3 ,

75 MHz): 163.7, 158.6, 158.0, 154.0, 144.1, 135.7, 135.5, 135.1, 129.9, 128.0, 127.9, 127.1, 127.0, 113.2, 105.6, 87.5, 87.0, 86.5, 71.6, 62.7, 55.1, 41.3, 16.4, 0.

5'-O-(4,4'-Dimethoxytrityl)-3'-O-trimethylsilyl-4-(1,2,4-triazol-1-yl)pyrimidin-2-one 2'-deoxyribose (0.9 g, 1.31 mmol) was dissolved in dioxane and the solution was placed into a steel bomb. Ammonia was distilled on the bomb and the reaction was left overnight at 60 °C. The reaction mixture was treated as described for compound 1. The product was purified by column chromatography on silica gel (0% to 15% MeOH in DCM). Yield: 0.55 g (76%). TLC (10% MeOH in DCM) R_f 0.3. ¹H-NMR (CDCl₃, 300 MHz): 7.78 (1H, s), 7.43-7.23 (9H, m), 6.84 (4H, d, J=13.2 Hz), 6.30 (1H, t, J= 10.2 Hz), 4.48 (1H, m), 4.07 (1H, m), 3.80 (6H, s), 3.38 (2H, m), 2.46 (1H, m), 2.23 (1H, m), 1.46 (3H, s). ¹³C-NMR (CDCl₃, 75 MHz): 164.8, 158.3, 138.1, 135.8-135.2, 129.8, 127.8, 127.6, 126.7, 112.9, 102.6, 86.4, 86.0, 85.6, 71.1, 63.1, 54.9, 41.3, 12.0.

5'-O-(4,4'-Dimethoxytrityl)-N⁴-isobutyryl-5-methyl-2'-deoxycytidine (3).

5'-O-(4,4'-Dimethoxytrityl)-5-methyl-2'-deoxycytidine (490 mg, 0.9 mmol) were dissolved in 5 ml of pyridine and 167 mg of trimethylsilyl chloride (1.53 mmol) were added. After one hour of magnetic stirring at room temperature, 212 mg of isobutyric anhydride (1.34 mmol) were added. The reaction was stirred for 3 hours at room temperature and 0.5 ml of MeOH were added followed by 0.5 ml of water. Solvents were evaporated and the residue was purified by column chromatography on silica gel eluted with a gradient from 0 to 15% MeOH in DCM. Yield 350 mg (63%). TLC (15% MeOH in DCM) R_f 0.87. ¹H-NMR (CDCl₃, 200 MHz): 7.63 (1H, s), 6.77-7.42 (13H, m), 6.45 (1H, t, J= 3 Hz), 4.57 (1H, m), 4.10 (1H, m), 3.7 (6H, s), 3.41 (2H, m), 2.48 (1H, m), 2.22 (2H, m), 1.43 (3H, s), 1.17 (6H, d, J=8.5 Hz).

N⁴-(9-Fluorenylmethoxycarbonyl)-5-methyl-2'-deoxycytidine (4).

5-Methyl-2'-deoxycytidine (1 g, 4.14 mmol) was dissolved with 20 ml of pyridine and 1.8 ml (14.5 mmol) of trimethylsilyl chloride were added. After 1 hr of magnetic stirring at room temperature, 1.30 g (4.9 mmol) of Fmoc-Cl were added. After two hours, 10 ml of water were added and the mixture was stirred overnight. The reaction mixture was concentrated to dryness and the residue was purified by column chromatography on silica gel (0 % to 10% MeOH in DCM). Yield: 370 mg (20%). TLC (10% MeOH in DCM) R_f 0.3. ¹H-NMR (DMSO-d₆, 250 MHz): 8.62 (1H, m), 7.30-8.0 (8H, m), 6.32 (1H, t, J=6.7Hz), 5.3 (1H, t), 5.2 (1H, t), 4.5 (2H, d), 4.25 (2H, m), 3.9 (1H, m), 3.68 (2H, m), 2.47 (2H, m), 1.90 (3H, s). ¹³C-NMR (DMSO-d₆, 63 MHz): 143.7, 140.6, 127.5, 127.0, 124.9, 120.0, 87.6, 84.9, 69.9, 66.5, 60.9, 54.8, 46.4, 13.2.

5'-O-(4,4'-Dimethoxytrityl)-N⁴-(9-fluorenylmethoxycarbonyl)-5-methyl-2'-deoxycytidine (5).

N⁴-Fmoc-5-methyl-2'-deoxycytidine (370 mg, 0.8 mmol) was dissolved in 8 ml of pyridine and 324 mg of DMT chloride (0.96 mmol) were added. After 3 hours of magnetic stirring at room temperature, 2 ml of MeOH were added. Solvents were evaporated and the residue was dissolved in DCM and washed twice with a 1M NaHCO₃ aqueous solution. The organic phase was dried and concentrated to dryness. The residue was purified by column chromatography on silica gel (0% to 10 % MeOH in DCM). Yield: 250 mg (41%). TLC (5% MeOH in DCM) R_f 0.87. ¹H-NMR (DMSO-d₆, 250 MHz): 8.5 (1H, m), 6.77-7.73 (m), 6.35 (1H, t, J = 6.6 Hz), 4.56 (1H, m), 4.35 (2H, m), 4.06 (1H, m), 3.7 (7H, s), 3.34 (2H, m), 2.35 (2H, m), 1.52 (3H, s).

5'-O-(4,4'-Dimethoxytrityl)-N⁴-(9-fluorenylmethoxycarbonyl)-5-methyl-2'-deoxycytidine 3'-O-(N,N-diisopropyl)-2-cyanoethyl phosphoramidite (6).

5'-O-DMT-N⁴-Fmoc-5-methyl-2'-deoxycytidine (1.23 g, 1.61 mmol) was dissolved in 2 ml of dry DCM and the solution was kept under argon on an ice-water bath. To the solution, 0.84 ml (6.44 mmol) of N,N-diisopropylethylamine were added dropwise with a syringe followed by 0.53 ml (2.4 mmol) of 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine. After 1 hour of magnetic stirring at room temperature, the reaction mixture was diluted with more DCM and washed with 1M NaHCO₃ aqueous solution. The organic phase was dried and concentrated to dryness. The residue was purified by column chromatography on silica gel eluted with hexane-AcOEt (2:1) containing 1% of triethylamine. Yield: 920 mg (60%). TLC (hexane: AcOEt 1:2 containing 1% triethylamine) R_f 0.29. ³¹P-NMR (CH₃CN, 101 MHz): 145.6 ppm.

5'-O-(4,4'-Dimethoxytrityl)-N⁴-[2-(4-nitrophenyl)ethoxycarbonyl]-5-methyl-2'-deoxycytidine (7).

5-Methyl-2'-deoxycytidine (1.1 g, 4.6 mmol) was dissolved in dry DMF and 1.9 ml of hexamethyldisilazane (9.2 mmol) were added. After 30 min of magnetic stirring at room temperature solvents were evaporated to dryness, the residual oil was dissolved in 50 ml of MeOH / DMF (1 : 1) and again solvents were concentrated. The product was dried twice with 20 ml of dry pyridine and the residue was dissolved in 100 ml of dry pyridine. The solution was cooled in an ice bath and 1.58 g (6.9 mmol) of Npeoc-Cl¹⁷ were added. After two hours, 20 ml of MeOH were added and the mixture was evaporated to dryness. The residual oil was dissolved with CHCl₃ (300 ml) and the organic solution was washed with 300 ml of 1M NaHCO₃ aqueous solution. The organic phase was dried and

concentrated to dryness. The product was dissolved in DCM and a solution of 2.28 g (11.5 mmol) of *p*-toluenesulfonic acid in 100 ml of THF was added to remove the trimethylsilyl groups. After 20 min, 2.8 ml (20 mmol) of triethylamine were added and the mixture was stirred for 5 min. Solvent was removed and the residual oil was purified by column chromatography on silica gel (7-20 % MeOH gradient in CHCl₃). The fractions containing the product were pooled and evaporated to dryness obtaining 1.19 g (2.7 mmol, 59%) of an oil that contained the desired product (judged by NMR) with some impurities.

The product obtained above was dissolved in 20 ml of dry pyridine and reacted with 2.2 g (6.5 mmol) of DMT chloride as described for compound 5. Yield 40% from m⁵dC (1.32 g, 1.8 mmol). TLC (5% EtOH / DCM) R_f: 0.5. ¹H-NMR (CDCl₃, 300 MHz): 12.2 (1H, s), 8.1 (2H, d, J = 8.7 Hz), 7.71 (1H, s), 7.42 (4H, d, J = 9 Hz), 7.1 (7H, m), 6.84 (4H, d, J = 9 Hz), 6.37 (1H, t, J = 6 Hz), 4.58 (1H, m), 4.39 (2H, t, J = 7.2 Hz), 4.06 (1H, m), 3.79 (6H, s), 3.50 (1H, dd J = 10.5 and 3 Hz), 3.37 (1H, dd, J 10.5 and 3 Hz), 3.13 (2H, t, J = 7.2 Hz), 2.45 (1H, m), 2.32 (1H, m), 1.5 (3H, s). ¹³C-NMR (DMSO-d₆, 63 MHz): 163.4, 160.8, 158.6, 147.8, 146.7, 145.6, 144.1, 136.8, 135.3, 129.9, 129.6, 128.0, 127.8, 127.0, 123.5, 113.1, 110.9, 86.6, 86.4, 85.3, 71.8, 65.1, 63.3, 55.0, 41.1, 34.8, 12.6.

Oligonucleotide synthesis and purification.

Sequences A: [5'(Br⁵U-m⁵C)₉ 3']; B (s₁₁-m⁵CBr⁵U): 5' m⁵C-Br⁵U-Br⁵U-m⁵C-m⁵C-Br⁵dUmdC-m⁵C-Br⁵U-m⁵C-Br⁵U 3'); C (h₂₆): 5'GAAGGAGGAGATTTTCTCCTCCTTC 3'; D (s₁₁-CT): 5' CTTCCTCCTCT 3'; E (s₁₁-m⁵CT): m⁵C-T-T-m⁵C-m⁵C-T-m⁵C-m⁵C-T-m⁵C-T 3'; and F (s₁₁-CBr⁵U): C-Br⁵U-Br⁵U-C-C-Br⁵U-C-C-Br⁵U-C-Br⁵U 3' were assembled using 35 mg of solid support and the appropriate protected nucleoside phosphoramidites on an automatic DNA synthesizer (Applied Biosystems Mod. 392). Tri phosphoramidite was prepared as described^{12, 13} and was also obtained from Glen Research. Both products gave identical results. The standard 1 μmol scale synthesis cycle was used. In all cases the last DMT group was left to help purification. Coupling efficiencies were 99% except for the Fmoc-m⁵C phosphoramidite that was 95%.

Sequences A and B prepared using Fmoc-m⁵dC phosphoramidite were deprotected as follows : the supports were treated with a 0.5 M DBU solution in *anhydrous* DCM (2-3 ml) at room temperature for 15 minutes (5 treatments of 3 minutes each). The support was washed with acetonitrile, water, 2% ammonium acetate aqueous solution and acetonitrile. The supports were dried at vacuum and transferred to a screw-cap flask. 1.5 ml of concentrated ammonia were added and the treatment was prolonged overnight at room

temperature. The support was filtered and the solutions were used directly for purification using COP™ cartridges.

Sequence F was prepared using C phosphoramidite protected with isobutryl group and the ammonia deprotection was performed at room temperature overnight.

The rest of the sequences were deprotected using standard protocols¹⁸ or as described in table 1.

Oligonucleotides with the DMT group at the 5'-end were purified using COP™ cartridges following the instructions of the manufacturers. Further purification was achieved by reversed-phase HPLC. HPLC conditions were as follows : Column : Nucleosil 120C18 (200 x 4 mm), flow rate 1 ml / min, a 20 min linear gradient from 2 to 25% acetonitrile over 20 mM aqueous triethylammonium acetate. Overall (synthesis and purification) yields were around 40-50%.

Nucleoside composition were analyzed by enzyme digestion followed by HPLC analysis. The polymers (20-40 µg) were incubated in 50 mM tris HCl pH 8.0 and 10 mM magnesium chloride with snake venom phosphodiesterase (Boehringer-Mannheim, 1 µl) and alkaline phosphatase (Boehringer-Mannheim, 1 µl) in a total volume of 20 µl at 37 °C overnight. The resulting mixture was analysed by HPLC using the conditions described above.

Melting studies.

Solutions of equimolar amounts of the hairpin oligonucleotide (h₂₆) and the appropriate elevenmer (s₁₁) were mixed in the appropriate buffer. The solutions were heated at 80 °C and allowed to cool slowly to room temperature and samples were kept in the refrigerator overnight. UV absorption spectra and melting experiments (absorbance vs temperature) were recorded in 1 cm path-length cells a spectrophotometer, which has a temperature controller with a programmed temperature increase of 0.5 deg min⁻¹. Melts were run on duplex concentration of 4 µM at 270 nm.

ACKNOWLEDGEMENTS

We are grateful to CICYT (PB92-0043) and E.E.C.C. Biomedicine and Health Programme (BMH1-CT93-1669) for financial support. We thank Drs. Matthias Mann and Matthias Wilm for obtaining mass spectra.

REFERENCES

1. Hélène, C., and Toulmé, J.J. *Biochim. Biophys. Acta*, **1990**, *1049*, 99-125.

2. Hélène, C. *Anti-Cancer Drug Des.*, **1991**, *6*, 569-584.
3. Xodo, L.E., Manzini, G., Quadrifoglio, F., van der Marel, G.A., and van Boom, J.H. *Nucleic Acids Res.*, **1991**, *19*, 5625-5631.
4. Povsic, T.J., and Dervan, P.B. *J. Am. Chem. Soc.*, **1989**, *111*, 3059-3061.
5. Sowers, L.C., Goodman, M.F., Eritja, R., Kaplan, B., and Fazakerley, G.V. *J. Mol. Biol.*, **1989**, *205*, 437-447.
6. Yu, H., Eritja, R. Bloom, L.B., and Goodman, M.F. *J. Biol. Chem.*, **1993**, *268*, 15935-15943.
7. Schulhof, J.C., Molko, D. and Teoule, R. *Nucleic Acids Res.*, **1987**, *15*, 397-416.
8. Roberts, M., and Visser, D.W. *J. Am. Chem. Soc.*, **1952**, *74*, 668.
9. Goldman, D., and Kalman, T.I. *Nucleosides & Nucleotides* **1983**, *2*, 175-187.
10. Lipkin, D., Cori, C.T., and Rabi, J.A. *J. Heterocyclic Chem.* **1969**, *6*, 995.
11. Peninsula Laboratories technical bulletin.
12. Webb, T.R. and Matteucci, M.D. *Nucleic Acids Res.*, **1986**, *14*, 7661-7674.
13. Roelen, H., Brugghe, H.F., van der Elst, H. van der Marel, G.A., van Boom, J.H. *Rcl. Trav. Chim. Pays-Bas*, **1992**, *111*, 99.
14. Vorbrüggen, H., Krolkiewicz, K. in *Nucleic Acid Chemistry. Part one*. Townsend, L.B., Tipson, R. John Wiley & sons, New York, 1978, pp 227-229.
15. Sung, W.L. *J.C.S. Chem. Comm.*, **1981**, 1089.
16. Koole, L.H., Moody, H.M., Broeders, N., Quaedflieg, P., Kuijpers, W., van Genderen, M., Coenen, A., van der Wal, S. and Buck, H.M. *J. Org. Chem.*, **1989**, *54*, 1657-1664.
17. Himmelsbach, F., Schulz, B.S., Trichtinger, T., Charubala, R., Pfeleiderer, W. *Tetrahedron*, **1984**, *40*, 59-72.
18. Eckstein, F. (Ed.) in *Oligonucleotides and analogues. A practical approach* Oxford University Press, Oxford 1991.
19. Lee, J.S., Woodsworth, M.L., Latimer, L.J.P., Morgan, A.R. *Nucleic Acids Res.*, **1984**, *12*, 6603.
20. Morvan, F., Chaix, C., Zeissler, A., Rayner, B., Imbach, J.L. *Nucleosides & Nucleotides* **1995**, *14*, 975-977.

Received September 5, 1995

Accepted November 30, 1995